Evidence map›Paper›PMID 27464732›Full record

ArticleBMC cancer2016

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.

Jan Baumann, Jason Wong, Yan Sun, Douglas S Conklin

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. LifelongNutrients · 2026
    Article
  4. Metabolic hallmarks of trastuzumab resistance.Expert opinion on therapeutic targets · 2025
    Review
  5. Article
  6. Review
  7. Endoplasmic reticulum stress targeted therapy for breast cancer.Cell communication and signaling : CCS · 2022
    Review
  8. Lipophilic and Hydrophilic Compounds fromLife (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jan BaumannDepartment of Biomedical Sciences, Cancer Research Center, State University of New York, University at Albany, Rensselaer, NY, 12144, USA.
Jason WongDepartment of Biomedical Sciences, Cancer Research Center, State University of New York, University at Albany, Rensselaer, NY, 12144, USA.
Yan SunDepartment of Biomedical Sciences, Cancer Research Center, State University of New York, University at Albany, Rensselaer, NY, 12144, USA.
Douglas S ConklinDepartment of Biomedical Sciences, Cancer Research Center, State University of New York, University at Albany, Rensselaer, NY, 12144, USA. dconklin@albany.edu.
New York University · USUniversity at Albany, State University of New York · US

Funding

NR1D1 pathway in breast cancerR01CA136658 · NCI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI CONKLIN, DOUGLAS S. · 2009 to 2012
$1.2M
NCI NIH HHS R01 CA136658
6 · The paper itself

Abstract

backgroundHER2/neu-positive breast cancer cells have recently been shown to use a unique Warburg-like metabolism for survival and aggressive behavior. These cells exhibit increased fatty acid synthesis and storage compared to normal breast cells or other tumor cells. Disruption of this synthetic process results in apoptosis. Since the addition of physiological doses of exogenous palmitate induces cell death in HER2/neu-positive breast cancer cells, the pathway is likely operating at its limits in these cells. We have studied the response of HER2/neu-positive breast cancer cells to physiological concentrations of exogenous palmitate to identify lipotoxicity-associated consequences of this physiology. Since epidemiological data show that a diet rich in saturated fatty acids is negatively associated with the development of HER2/neu-positive cancer, this cellular physiology may be relevant to the etiology and treatment of the disease. We sought to identify signaling pathways that are regulated by physiological concentrations of exogenous palmitate specifically in HER2/neu-positive breast cancer cells and gain insights into the molecular mechanism and its relevance to disease prevention and treatment.

methodsTranscriptional profiling was performed to assess programs that are regulated in HER2-normal MCF7 and HER2/neu-positive SKBR3 breast cancer cells in response to exogenous palmitate. Computational analyses were used to define and predict functional relationships and identify networks that are differentially regulated in the two cell lines. These predictions were tested using reporter assays, fluorescence-based high content microscopy, flow cytometry and immunoblotting. Physiological effects were confirmed in HER2/neu-positive BT474 and HCC1569 breast cancer cell lines.

resultsExogenous palmitate induces functionally distinct transcriptional programs in HER2/neu-positive breast cancer cells. In the lipogenic HER2/neu-positive SKBR3 cell line, palmitate induces a G2 phase cell cycle delay and CHOP-dependent apoptosis as well as a partial activation of the ER stress response network via XBP1 and ATF6. This response appears to be a general feature of HER2/neu-positive breast cancer cells but not cells that overexpress only HER2/neu. Exogenous palmitate reduces HER2 and HER3 protein levels without changes in phosphorylation and sensitizes HER2/neu-positive breast cancer cells to treatment with the HER2-targeted therapy trastuzumab.

conclusionsSeveral studies have shown that HER2, FASN and fatty acid synthesis are functionally linked. Exogenous palmitate exerts its toxic effects in part through inducing ER stress, reducing HER2 expression and thereby sensitizing cells to trastuzumab. These data provide further evidence that HER2 signaling and fatty acid metabolism are highly integrated processes that may be important for disease development and progression.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell CycleCell Line, TumorCell ProliferationEndoplasmic Reticulum StressErb-b2 Receptor Tyrosine KinasesFatty Acid Synthase, Type IFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMCF-7 CellsPalmitatesSignal TransductionTrastuzumabAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFASN protein, humanFatty Acid Synthase, Type IPalmitatesTrastuzumabERBB2ER stressHER2/neuHigh fat dietMetabolismPalmitateSaturated fatTrastuzumab

Identifiers

PMID27464732
PMCPMC4964104
OpenAlexW2506470979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.